Commentary|Articles|September 15, 2026

A first for advanced RP: Bakall on the MOGENRY BLA acceptance and what an in-office option would mean

Author(s)Kassi Filkins, Benjamin Bakall, MD, PhD

Benjamin Bakall, MD, PhD, weighs the RESTORE efficacy and safety data, the practical realities of in-office delivery, and how genotype-independent treatment reshapes candidacy and patient counseling.

The US Food and Drug Administration (FDA) recently accepted Nanoscope Therapeutics’ biologics license application (BLA) for sonpiretigene isteparvovec (MOGENRY, formerly MCO-010), an investigational gene-agnostic optogenetic therapy for retinitis pigmentosa (RP) with severe vision loss.